A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer

Background. Anlotinib hydrochloride is an oral small molecule inhibitor of multiple tyrosine kinases, and it has been approved as a third-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) in China. This dose-exploration study was designed to investigate the feasibility of an...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Meijuan, Liu, Yongmei, Yu, Min, Li, Yanying, Zhang, Yan, Zhu, Jiang, Li, Li, Lu, You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993710/
https://www.ncbi.nlm.nih.gov/pubmed/34724131
http://dx.doi.org/10.1007/s10637-021-01179-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993710/
https://www.ncbi.nlm.nih.gov/pubmed/34724131
http://dx.doi.org/10.1007/s10637-021-01179-2

Ejemplares similares